title: Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc.
abstract: The clinical significance of a semi-quantitative microparticle enzyme immunoassay (IMx Core-M, Abbott) was evaluated for detection of IgM-class antibodies against the hepatitis B core antigen (IgM anti-HBc) in 136 hepatitis B surface antigen (HBsAg) positive individuals (96 chronic HBV carriers, 20 patients with chronic HBV-HDV infections and 20 patients with acute hepatitis B) and 50 HBV-negative controls. Baseline and follow-up sera (4-11 samples) were analysed from 79 carriers with chronic hepatitis B, 44 of whom were treated with interferon. IMx indexes above 3,000 were found in 95% of the acute hepatitis B patients and above 0.300 in 91.5% of patients with ongoing chronic hepatitis B. IMx indexes between 0.200 and 0.300 were observed in (a) patients with recent HBeAg to anti-HBe seronconversion (6-12 months) and normal serum ALT levels, (b) patients immuno-tolerant to HBV infection and without liver disease despite high levels of viremia, and (c) patients with anti-HBe-positive chronic hepatitis B during 7-13-month intervals of asymptomatic carriage between episodes of disease reactivation. IMx indexes below 0.200 were detected in all HBV-negative individuals and healthy HBV carriers, in 14 (70%) of 20 chronic hepatitis D patients and in all but 1 of 22 interferon-treated patients with histological remission of liver disease, 5-12 months after clearance of viremia and normalization of serum ALT levels. In contrast, IMx indexes remained above 0.200 in all patients with hepatitis B reactivation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Gastroenterology, Molinette Hospital, Torino, Italy.
authors.forename: M R
authors.initials: MR
authors.lastname: Brunetto
authors.forename: M T
authors.initials: MT
authors.lastname: Cerenzia
authors.forename: F
authors.initials: F
authors.lastname: Oliveri
authors.forename: P
authors.initials: P
authors.lastname: Piantino
authors.forename: A
authors.initials: A
authors.lastname: Randone
authors.forename: P L
authors.initials: PL
authors.lastname: Calvo
authors.forename: P
authors.initials: P
authors.lastname: Manzini
authors.forename: G
authors.initials: G
authors.lastname: Rocca
authors.forename: C
authors.initials: C
authors.lastname: Galli
authors.forename: F
authors.initials: F
authors.lastname: Bonino
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001331:Automation; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000097:blood / Q000628:therapy*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007075:Immunoglobulin M / Q000097:blood*; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010316:Particle Size
chemical_list: D006512:Hepatitis B Core Antigens; D007075:Immunoglobulin M; D007372:Interferons